• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

SGLT2 Inhibitors and Cardiovascular Outcomes Trials: 4 Questions

Article

Refresh your memory on findings from the EMPA-REG OUTCOME, CANVAS, CREDENCE, and DECLARE-TIMI cardiovascular outcomes trials on SGLT2 inhibitors.

Cardiovascular (CV) outcomes trials have generally shown that sodium–glucose cotransporter 2 inhibitors (SGLT2i) decrease CV risk in patients with type 2 diabetes mellitus (T2DM). Major CV outcomes randomized controlled trials (RCTs) for this class of drugs include:

  • EMPA-REG OUTCOME: 7020 participants with T2DM at high CV risk randomized to empagliflozin or placebo; median follow-up of 3.1 years
  • DECLARE-TIMI: 17 160 participants with T2DM at high CV risk randomized to dapagliflozin or placebo; median follow-up of 4.2 years
  • CREDENCE: 4401 participants with T2DM and chronic kidney disease randomized to canagliflozin or placebo; median follow-up of 2.62 years
  • CANVAS: 10 142 participants with T2DM at high CV risk randomized to canagliflozin or placebo; median follow-up of 3.6 years

Test your knowledge on the 4 major CV outcomes RCTs for SGLT2i with the 8-question quiz below.


1. Which trial failed to find significantly decreased 3-point major adverse CV events (MACE) in patients with T2DM?

A. EMPA-REG OUTCOME
B. DECLARE-TIMI
C. CANVAS
D. CREDENCE


Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
© 2024 MJH Life Sciences

All rights reserved.